TrialAnnals of oncology : official journal of the European Society for Medical Oncology2018

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.

L Malorni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.